Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,680 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Spinal Metastases
Interventions: single-fraction SRS, high-dose hypofractionated SRS, Quality of Life Measures; Radiation · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: Not listed
Lead sponsor: Lotus Tissue Repair, Inc.; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bacterial Disease Carrier, Cystic Fibrosis
Interventions: Placebo, WRAIR-PAM-CF1; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-Onset), Acid Maltase Deficiency Disease, Glycogenosis 2
Interventions: alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA]); Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
U.S. locations: 74
States / cities: Sheffield, Alabama • Anchorage, Alaska • Phoenix, Arizona + 71 more

Conditions: Epidermolysis Bullosa Simplex
Interventions: diacerein 1% ointment, A placebo ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Autism Spectrum Disorder, Restricted Behavior, Autism
Interventions: Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mild Cognitive Impairment, Subjective Cognitive Impairment
Interventions: pSOPT, MLA; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 60 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: X-Linked Adrenoleukodystrophy (X-ALD), Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD)
Interventions: Allo-HSCT; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 3 more

Conditions: Cancer
Interventions: SNX-5422; Drug
Lead sponsor: Esanex Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Scottsdale, Arizona • Stanford, California • Washington D.C., District of Columbia + 2 more

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Prolonged exposure; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Epilepsy
Interventions: lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 41
States / cities: Mobile, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
Interventions: CMV hyperimmune globulin, Placebo; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 399 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Heart Failure, Systolic
Interventions: Autologous cell therapy, Sham; Biological · Other
Lead sponsor: BioCardia, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Myotonic Dystrophy Type 1
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Stroke, Acute, Cerebral Infarction
Interventions: Neofect RAPAEL Smart Glove; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Palo Alto, California • San Jose, California • Salt Lake City, Utah

Conditions: Macular Degeneration, Retinal Drusen
Interventions: Pascal Retinal Laser Photocoagulator; Device
Lead sponsor: Stanford University; Other
Eligibility: 60 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Liver Cirrhosis, Biliary
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 43
States / cities: Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more

Conditions: Obsessive Compulsive Disorder
Interventions: Troriluzole (BHV-4157); Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 772 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 147
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 119 more

Conditions: Thalassemia
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • Oakland, California • Stanford, California + 5 more

Conditions: Cigarette Smoker, Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Pulmonary Nodule
Interventions: Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography (PET/CT); Diagnostic Test · Drug
Lead sponsor: Andrei Iagaru; Other
Eligibility: 45 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
Interventions: Exa-cel; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York + 4 more

Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Interventions: Not listed
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Redwood City, California • Baltimore, Maryland • Columbia, Maryland + 3 more

Conditions: Multiple Myeloma
Interventions: high dose chemotherapy then autologous hematopoietic cell transplant; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Mild Cognitive Impairment, Cognitive Decline, Memory Impairment
Interventions: Aerobic exercise, Stretching/balance/range of motion exercise; Behavioral
Lead sponsor: Alzheimer's Disease Cooperative Study (ADCS); Other
Eligibility: 65 Years to 89 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 14
States / cities: Irvine, California • Palo Alto, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases

Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Alglucosidase Alfa Temporary Access Program

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth

CogT pSOPT Intervention Study

Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)

Pediatric Epilepsy Study in Subjects 1-24 Months

A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

CardiAMP™ Cell Therapy for Heart Failure Trial

Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy

Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

Exercise in Adults With Mild Memory Problems